CN113646328A - 一种免疫细胞因子及其制备与用途 - Google Patents

一种免疫细胞因子及其制备与用途 Download PDF

Info

Publication number
CN113646328A
CN113646328A CN202080009757.0A CN202080009757A CN113646328A CN 113646328 A CN113646328 A CN 113646328A CN 202080009757 A CN202080009757 A CN 202080009757A CN 113646328 A CN113646328 A CN 113646328A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
antibody
immunocytokine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080009757.0A
Other languages
English (en)
Other versions
CN113646328B (zh
Inventor
王峰
郑花鸯
张雨菡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nantong Yichen Biomedical Technology Co ltd
Original Assignee
Nantong Yichen Biomedical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nantong Yichen Biomedical Technology Co ltd filed Critical Nantong Yichen Biomedical Technology Co ltd
Publication of CN113646328A publication Critical patent/CN113646328A/zh
Application granted granted Critical
Publication of CN113646328B publication Critical patent/CN113646328B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明提供了一种IL‑15与IL‑15Ra分别融合在靶向细胞表面抗原的抗体的免疫细胞因子，可有效地将IL‑15与IL‑15Ra的复合物特异性靶向肿瘤微环境，激活肿瘤内或附近的相关免疫细胞，达到特异性杀伤肿瘤的目标，同时可以避免因全身性过度激活NK细胞诱导的免疫毒性。

Description

PCT国内申请，说明书已公开。

Claims (23)

  1. PCT国内申请，权利要求书已公开。
CN202080009757.0A 2019-08-19 2020-08-19 一种免疫细胞因子及其制备与用途 Active CN113646328B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910764762 2019-08-19
CN2019107647621 2019-08-19
PCT/CN2020/109986 WO2021032116A1 (zh) 2019-08-19 2020-08-19 一种免疫细胞因子及其制备与用途

Publications (2)

Publication Number Publication Date
CN113646328A true CN113646328A (zh) 2021-11-12
CN113646328B CN113646328B (zh) 2024-03-26

Family

ID=74659948

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080009757.0A Active CN113646328B (zh) 2019-08-19 2020-08-19 一种免疫细胞因子及其制备与用途

Country Status (4)

Country Link
US (1) US20220289838A1 (zh)
EP (1) EP4019536A4 (zh)
CN (1) CN113646328B (zh)
WO (1) WO2021032116A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107208099A (zh) * 2015-02-06 2017-09-26 热生物制品有限公司 共表达疫苗和共刺激分子的载体

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
WO2023222886A1 (en) * 2022-05-20 2023-11-23 Depth Charge Ltd Antibody-cytokine fusion proteins

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3039930A1 (en) * 2016-10-14 2018-04-19 Xencor, Inc. Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
CN108948177A (zh) * 2007-05-11 2018-12-07 阿尔托生物科学有限公司 融合分子与il-15变异体
CN109715196A (zh) * 2016-06-13 2019-05-03 转矩医疗股份有限公司 用于促进免疫细胞功能的组合物和方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005085282A1 (en) 2004-02-27 2005-09-15 Inserm (Institut National De La Sante Et De La Recherche Medicale) Il-15 binding site for il15-ralpha and specific il-15 mutants having agonists/antagonists activity
RU2573915C2 (ru) 2009-09-16 2016-01-27 Дженентек, Инк. Содержащие суперспираль и/или привязку белковые комплексы и их применение
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
WO2018075989A1 (en) * 2016-10-21 2018-04-26 Altor Bioscience Corporation Multimeric il-15-based molecules
EP3648786A4 (en) * 2017-07-03 2021-12-15 Torque Therapeutics, Inc. FUSION MOLECULES TARGETING IMMUNE REGULATORY CELLS AND THEIR USES

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108948177A (zh) * 2007-05-11 2018-12-07 阿尔托生物科学有限公司 融合分子与il-15变异体
CN109715196A (zh) * 2016-06-13 2019-05-03 转矩医疗股份有限公司 用于促进免疫细胞功能的组合物和方法
CA3039930A1 (en) * 2016-10-14 2018-04-19 Xencor, Inc. Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107208099A (zh) * 2015-02-06 2017-09-26 热生物制品有限公司 共表达疫苗和共刺激分子的载体

Also Published As

Publication number Publication date
WO2021032116A1 (zh) 2021-02-25
EP4019536A1 (en) 2022-06-29
CN113646328B (zh) 2024-03-26
US20220289838A1 (en) 2022-09-15
EP4019536A4 (en) 2023-09-06

Similar Documents

Publication Publication Date Title
US11679127B2 (en) Antigen binding receptors specific for mutated Fc domains
US11026975B2 (en) Chimeric antigen receptor (CAR) binding to BCMA, and uses thereof
JP2022046809A (ja) キメラ抗原受容体及びその使用方法
US7262276B2 (en) Anti human ovarian cancer-anti CD3 bispecific antibody
US20200093861A1 (en) Antigen binding receptor formats
CN113646328A (zh) 一种免疫细胞因子及其制备与用途
JP2018523484A (ja) 細胞
JP7365654B2 (ja) 抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体
JP2024112828A (ja) 消化管系へのペイロード送達のための、ｂｔｎｌ３／８を標的とする構築物
KR20230160294A (ko) Upar 항체 및 이를 갖는 융합 단백질
US20240218065A1 (en) Multispecific antigen-binding protein and use thereof
JP2024511465A (ja) Ｎｋ細胞エンゲージングのためにサイトカインに融合したｎｋｐ４６結合性部位、がん抗原結合性部位を含む多特異性タンパク質
TW202342734A (zh) 具有抗-cd19/抗-cd22嵌合抗原受體之基因工程細胞及其用途
WO2020135804A1 (zh) 异源二聚体融合蛋白
US20230303660A1 (en) Co-stimulatory 4-1bbl ectodomain polypeptides for immunomodulation
KR20230131210A (ko) 조건부 이중특이성 결합 단백질
Huo et al. Development of a T cell-redirecting bispecific antibody targeting B-cell maturation antigen for the suppression of multiple myeloma cell growth
JP2023510806A (ja) Ｍａｉｔ及び腫瘍細胞の両方に結合する多重特異性抗体
US20240174768A1 (en) Bispecific antibodies enhancing cell mediated immune responses
WO2024103017A2 (en) Genetically engineered cells having anti-nectin4 chimeric antigen receptors, and uses thereof
TW202434635A (zh) 多特異性抗體及其醫藥用途
TW202334226A (zh) 改良之抗原結合受體
TW202334204A (zh) 條件性活化之抗原結合多肽複合物及其使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant